532 related articles for article (PubMed ID: 16129834)
1. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
2. Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Bergo MO; Toth JI; Qiao X; Hu Y; Sandoval S; Meta M; Bendale P; Gelb MH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10291-6. PubMed ID: 16014412
[TBL] [Abstract][Full Text] [Related]
3. Prelamin A farnesylation and progeroid syndromes.
Young SG; Meta M; Yang SH; Fong LG
J Biol Chem; 2006 Dec; 281(52):39741-5. PubMed ID: 17090536
[TBL] [Abstract][Full Text] [Related]
4. N6-isopentenyladenosine improves nuclear shape in fibroblasts from humans with progeroid syndromes by inhibiting the farnesylation of prelamin A.
Bifulco M; D'Alessandro A; Paladino S; Malfitano AM; Notarnicola M; Caruso MG; Laezza C
FEBS J; 2013 Dec; 280(23):6223-32. PubMed ID: 24112551
[TBL] [Abstract][Full Text] [Related]
5. Blocking protein farnesylation improves nuclear shape abnormalities in keratinocytes of mice expressing the prelamin A variant in Hutchinson-Gilford progeria syndrome.
Wang Y; Ostlund C; Worman HJ
Nucleus; 2010; 1(5):432-9. PubMed ID: 21326826
[TBL] [Abstract][Full Text] [Related]
6. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
7. Prelamin A and lamin A appear to be dispensable in the nuclear lamina.
Fong LG; Ng JK; Lammerding J; Vickers TA; Meta M; Coté N; Gavino B; Qiao X; Chang SY; Young SR; Yang SH; Stewart CL; Lee RT; Bennett CF; Bergo MO; Young SG
J Clin Invest; 2006 Mar; 116(3):743-52. PubMed ID: 16511604
[TBL] [Abstract][Full Text] [Related]
8. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A.
Liu Y; Rusinol A; Sinensky M; Wang Y; Zou Y
J Cell Sci; 2006 Nov; 119(Pt 22):4644-9. PubMed ID: 17062639
[TBL] [Abstract][Full Text] [Related]
9. [A-type lamins and progeroïd syndromes : persistent farnesylation with dramatic effects].
Navarro CL; Poitelon Y; Lévy N
Med Sci (Paris); 2008 Oct; 24(10):833-40. PubMed ID: 18950579
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP; Huyer G; Bendale P; Gelb MH; Michaelis S
Proc Natl Acad Sci U S A; 2005 Oct; 102(40):14416-21. PubMed ID: 16186497
[TBL] [Abstract][Full Text] [Related]
11. Abnormal nuclear morphology is independent of longevity in a zmpste24-deficient fish model of Hutchinson-Gilford progeria syndrome (HGPS).
Tonoyama Y; Shinya M; Toyoda A; Kitano T; Oga A; Nishimaki T; Katsumura T; Oota H; Wan MT; Yip BWP; Helen MOL; Chisada S; Deguchi T; Au DWT; Naruse K; Kamei Y; Taniguchi Y
Comp Biochem Physiol C Toxicol Pharmacol; 2018 Jul; 209():54-62. PubMed ID: 29567411
[TBL] [Abstract][Full Text] [Related]
12. Farnesylated lamins, progeroid syndromes and farnesyl transferase inhibitors.
Rusiñol AE; Sinensky MS
J Cell Sci; 2006 Aug; 119(Pt 16):3265-72. PubMed ID: 16899817
[TBL] [Abstract][Full Text] [Related]
13. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.
Young SG; Fong LG; Michaelis S
J Lipid Res; 2005 Dec; 46(12):2531-58. PubMed ID: 16207929
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
15. Identification of mitochondrial dysfunction in Hutchinson-Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture.
Rivera-Torres J; Acín-Perez R; Cabezas-Sánchez P; Osorio FG; Gonzalez-Gómez C; Megias D; Cámara C; López-Otín C; Enríquez JA; Luque-García JL; Andrés V
J Proteomics; 2013 Oct; 91():466-77. PubMed ID: 23969228
[TBL] [Abstract][Full Text] [Related]
16. Blocking farnesylation of the prelamin A variant in Hutchinson-Gilford progeria syndrome alters the distribution of A-type lamins.
Wang Y; Ostlund C; Choi JC; Swayne TC; Gundersen GG; Worman HJ
Nucleus; 2012; 3(5):452-62. PubMed ID: 22895092
[TBL] [Abstract][Full Text] [Related]
17. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
18. Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria.
Ibrahim MX; Sayin VI; Akula MK; Liu M; Fong LG; Young SG; Bergo MO
Science; 2013 Jun; 340(6138):1330-3. PubMed ID: 23686339
[TBL] [Abstract][Full Text] [Related]
19. A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria.
Fong LG; Frost D; Meta M; Qiao X; Yang SH; Coffinier C; Young SG
Science; 2006 Mar; 311(5767):1621-3. PubMed ID: 16484451
[TBL] [Abstract][Full Text] [Related]
20. Protein farnesyltransferase inhibitors and progeria.
Meta M; Yang SH; Bergo MO; Fong LG; Young SG
Trends Mol Med; 2006 Oct; 12(10):480-7. PubMed ID: 16942914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
